AstraZeneca’s Calquence plus venetoclax gains approval in US to treat CLL
AMPLIFY Phase III data showed 77% on Calquence plus venetoclax were progression free at three years.
Drug Development
Roche receives FDA acceptance for giredestrant combo NDA
Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research
Syngene and VivaMed collaborate on therapeutic programmes
Novartis enters licensing agreement with UNP for peptide therapeutics
MSD and Mayo Clinic team up to advance AI in drug development
Evogene and QUT partner on AI-based cancer therapies
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
